Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) unit Shandong Zibo Xincat Pharmaceutical recently obtained approval of azithromycin for suspension from China's National Medical Products Administration after it passed the regulator's quality and efficacy consistency evaluation, a Tuesday bourse filing said.
Azithromycin is a macrolide antibiotic suitable for the treatment of mild-to-moderate infections caused by certain designated microbial sensitive strains, according to the pharmaceuticals and chemical products company.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments